MedTrace Logo

5HT3 Antagonism and Auditory Gating in Schizophrenia

NCT00018850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2009-01-21

No results posted yet for this study

Summary

The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Conditions

Interventions

DRUG

ondansetron

BEHAVIORAL

neuropsychological testing

DRUG

nicotine

DRUG

haloperidol

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-06-30
Completion
2003-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00018850 on ClinicalTrials.gov